First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Investment to expand manufacturing and global medicine supply capacity
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Subscribe To Our Newsletter & Stay Updated
